Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Togashi

Showing results (71-80 of 156) with videos related to

Pageof 16
Sort By:
Clinical Pharmacokinetics|March 28, 2013
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancerMasahide Fukudo, Yasuaki Ikemi, Yosuke Togashi, et al.
Case Reports in Oncology|August 27, 2010
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene MutationKatsuhiro Masago, Yosuke Togashi, Masahide Fukudo, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 3, 2018
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancerAkihito Kawazoe, Kohei Shitara, Yasutoshi Kuboki, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2015
Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signalYosuke Togashi, Hidetoshi Hayashi, Kunio Okamoto, et al.
British Journal of Cancer|February 2, 2023
Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigensTakamasa Ishino, Shusuke Kawashima, Etsuko Tanji, et al.
Oncology|March 25, 2011
Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinibKatsuhiro Masago, Shiro Fujita, Yosuke Togashi, et al.
Cellular & Molecular Immunology|August 26, 2024
Fatty acid metabolism constrains Th9 cell differentiation and antitumor immunity via the modulation of retinoic acid receptor signalingTakahiro Nakajima, Toshio Kanno, Yuki Ueda, et al.
Case Reports in Oncology|September 17, 2010
Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung CancerAkiko Fukuhara, Katsuhiro Masago, Masashi Neo, et al.
Cancer Science|May 31, 2016
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Eri Banno, Yosuke Togashi, Yu Nakamura, et al.
International Journal of Oncology|April 26, 2017
Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinibEri Banno, Yosuke Togashi, Marco A de Velasco, et al.
Pageof 16

Showing results (71-80 of 156) with videos related to

Sort By:
Pageof 16
Clinical Pharmacokinetics|March 28, 2013
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancerMasahide Fukudo, Yasuaki Ikemi, Yosuke Togashi, et al.
Case Reports in Oncology|August 27, 2010
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene MutationKatsuhiro Masago, Yosuke Togashi, Masahide Fukudo, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 3, 2018
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancerAkihito Kawazoe, Kohei Shitara, Yasutoshi Kuboki, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2015
Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signalYosuke Togashi, Hidetoshi Hayashi, Kunio Okamoto, et al.
British Journal of Cancer|February 2, 2023
Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigensTakamasa Ishino, Shusuke Kawashima, Etsuko Tanji, et al.
Oncology|March 25, 2011
Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinibKatsuhiro Masago, Shiro Fujita, Yosuke Togashi, et al.
Cellular & Molecular Immunology|August 26, 2024
Fatty acid metabolism constrains Th9 cell differentiation and antitumor immunity via the modulation of retinoic acid receptor signalingTakahiro Nakajima, Toshio Kanno, Yuki Ueda, et al.
Case Reports in Oncology|September 17, 2010
Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung CancerAkiko Fukuhara, Katsuhiro Masago, Masashi Neo, et al.
Cancer Science|May 31, 2016
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Eri Banno, Yosuke Togashi, Yu Nakamura, et al.
International Journal of Oncology|April 26, 2017
Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinibEri Banno, Yosuke Togashi, Marco A de Velasco, et al.
Pageof 16